This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PFE, BNTX and MRNA Omicron Boosters Get Positive CHMP Opinion
by Ekta Bagri
Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) get positive CHMP opinion for Omicron-targeting bivalent booster.
The Zacks Analyst Blog Highlights Pfizer /BioNTec and Moderna's
by Zacks Equity Research
Pfizer /BioNTec and Moderna are part of The Zacks top Analyst Blog.
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DHS
FDA Authorizes Pfizer, Moderna's Omicron-Based Boosters
by Kinjel Shah
Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) develop the Omicron BA.4/BA.5-adapted bivalent vaccines at the FDA's recommendation.
Pharma Stock Roundup: FDA Authorization of Omicron Boosters, SNY's Xenpozyme & More
by Kinjel Shah
FDA authorizes Pfizer (PFE) & Moderna's (MRNA) Omicron-aimed COVID vaccines & Sanofi's (SNY) new drug, Xenpozyme.
Biotech Stock Roundup: BMY's Study Update, INCY's Drug Label Expansion, MRNA News
by Zacks Equity Research
Regulatory updates from Bristol Myers (BMY) and Incyte (INCY) are a few key highlights from the biotech sector during the past week.
Aerie (AERI) Rallies 205.6% in the Past Three Months: Here's Why
by Zacks Equity Research
Aerie (AERI) shares have skyrocketed in the past three months after the company announced its definitive agreement with Alcon, wherein the latter will acquire the former for $770 million.
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
Moderna's (MRNA) Omicron Based Jab gets Approval in Australia
by Zacks Equity Research
Moderna (MRNA) receives provisional approval in Australia for its Omicron-containing bivalent booster vaccine mRNA-1273.214 in adults, making it the first bivalent COVID-19 vaccine approved for use in Australia.
Pfizer (PFE), BioNTech Seek EU Nod for Omicron-Based Booster
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) complete submission of conditional marketing authorization to the European Medicines Agency for Omicron BA.4/BA.5-adapted bivalent vaccine.
Moderna (MRNA) Sues Pfizer and BioNTech Over COVID Jab
by Zacks Equity Research
Moderna (MRNA) sues Pfizer and BioNTech, alleging that Comirnaty infringes on patents that Moderna filed from 2010 to 2016 related to its mRNA technology.
The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer
by Zacks Equity Research
Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates
by Kinjel Shah
Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.
Pfizer (PFE) RSV Vaccine Found Effective in Older Adults
by Zacks Equity Research
Based on the positive data from the phase III study on its RSV vaccine candidate, Pfizer plans to file a biologics license application (BLA) to the FDA in fall 2022.
Akero Therapeutics (AKRO) Up on Positive NASH Study Data
by Zacks Equity Research
Akero Therapeutics (AKRO) announces positive data from third cohort of its mid-stage study evaluating efruxifermin (EFX) in NASH. Stock up.
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Morphic
by Zacks Equity Research
Pfizer, BioNTech, Moderna and Morphic are included in this Analyst Blog.
Pfizer (PFE), BioNTech Post Data on COVID Jab for Kids Under 5
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) report updated data, showing that their three-dose COVID-19 vaccine is 73.2% effective in children under five years.
Moderna (MRNA) Seeks FDA Nod for Omicron-Based COVID Jab
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID-19 booster vaccine, mRNA-1273.222, is designed to target the Omicron BA.4 and BA.5 subvariants. The vaccine has been developed specifically for the U.S. market.
Moderna (MRNA) to Supply Omicron-based COVID Jab in Canada
by Zacks Equity Research
Moderna's (MRNA) Omicron-specific bivalent vaccine booster is yet to be approved by Canadian health authorities. The government seeks to purchase 12 million doses of the same in 2022.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer (PFE), BioNTech Seek FDA Nod for Omicron Variant Booster
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccine contains mRNA encoding the spike protein present in the original vaccine as well as mRNA encoding the spike protein of the Omicron BA.4/BA.5 variant.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Novavax (NVAX) COVID-19 Vaccine Gets FDA Nod for Adolescents
by Zacks Equity Research
Post the label expansion by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in individuals aged 12 years and older in the United States.
Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down
by Zacks Equity Research
Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.